Small Molecule
Pipeline
Advancing a proprietary pipeline of innovative molecular therapies
We are committed to progressing a portfolio of first-in-class, disease-modifying therapeutics to provide new treatment options for patients.
Neurodon has identified specific cellular stress pathways that are responsible for the progression of such diverse conditions as neurodegenerative disease, diabetes, autoimmune disease, ischemia, and stroke. We have recognized the importance of this pathological mechanism and are committed to developing safe and effective molecular therapies addressing this feature.